Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

  • Gossamer Bio Inc GOSS announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). 
  • A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. 
  • An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm. 
  • Enhanced effects for both PVR and 6MWD were observed in patients with more severe baseline disease. 
  • Related: Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial.
  • In FC III patients, a 21% reduction in PVR and 37m improvement in 6MWD were observed for the seralutinib arm vs. placebo. 
  • Seralutinib treatment resulted in a statistically significant reduction in NT-proBNP, a biomarker of right heart stress, as early as 12 weeks, increasing to a 408.3 ng/L mean difference from placebo at Week 24.
  • Seralutinib was generally well tolerated in the TORREY study, with treatment-emergent adverse events (TEAEs) reported in 36 (86%) and 41 (93%) of the patients in the placebo and seralutinib arms, respectively. 
  • Price Action: GOSS shares are down 67.70% at $3.00 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!